March 26, 2026 · 0 shares
Investor-focused, cautiously optimistic promotional framing highlights mid-2026 enrollment for EB06 in vitiligo, cites prior data and regulatory context, and includes standard risk warnings to balance claims.
Public corporate release detailing a Phase 2 EB06 vitiligo program, timeline, trial design, data background, and regulatory/collaborative steps.
Skeptical of corporate PR; relies on disclosed data and risk warnings
2026 © Helium Trades
Privacy Policy & Disclosure
* Disclaimer: Nothing on this website constitutes investment advice, performance data or any recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Helium Trades is not responsible in any way for the accuracy
of any model predictions or price data. Any mention of a particular security and related prediction data is not a recommendation to buy or sell that security. Investments in securities involve the risk of loss. Past performance is no guarantee of future results. Helium Trades is not responsible for any of your investment decisions,
you should consult a financial expert before engaging in any transaction.
